Lamberti steps down from Schering AG supervisory board
German drugmaker Schering AG announced March 21 that Hermann-Josef Lamberti has stepped down, with immediate effect, from the group's supervisory board, "in order to avoid a conflict of interest."
What the conflict might be was not detailed by the company, but it is likely to be linked with Schering's rejection of the hostile 14.6 billion-euro ($17.53 billion) offer from fellow German group Merck KGaA (Marketletter March 20). Specifically, it is being suggested that this is because Mr Lamberti is on the management board of Deutsche Bank, which is advising Merck on the deal.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze